Amarin Corp ADR (AMRN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Amarin Corp ADR stock is currently priced at $0.8833, with a 24-hour trading volume of 763.55K. It has seen a +2.03% increased in the last 24 hours and a +2.75% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.8702 pivot point. If it approaches the $0.895 resistance level, significant changes may occur.

Amarin Corp ADR Stock (AMRN) Financials Data

Amarin Corp ADR (AMRN) Revenue 2024

AMRN reported a revenue (TTM) of $306.91 million for the quarter ending December 31, 2023, a -16.87% decline year-over-year.

Amarin Corp ADR (AMRN) Net Income 2024

AMRN net income (TTM) was -$59.11 million for the quarter ending December 31, 2023, a +44.13% increase year-over-year.

Amarin Corp ADR (AMRN) Cash Flow 2024

AMRN recorded a free cash flow (TTM) of $6.35 million for the quarter ending December 31, 2023, a +103.52% increase year-over-year.

Amarin Corp ADR (AMRN) Earnings per Share 2024

AMRN earnings per share (TTM) was -$0.15 for the quarter ending December 31, 2023, a +44.01% growth year-over-year.

Amarin Corp ADR Stock (AMRN) Latest News

Amarin Announces Results of Annual General Meeting of Shareholders

GlobeNewswire Inc.

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

GlobeNewswire Inc.

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

GlobeNewswire Inc.

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

Zacks Investment Research

Why Amarin Stock Was Rocketing Higher on Wednesday

The Motley Fool

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

GlobeNewswire Inc.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Upgrade	Jefferies: Hold → Buy	Jan-06-23
Downgrade	JP Morgan: Neutral → Underweight	May-06-22
Downgrade	H.C. Wainwright: Buy → Neutral	May-05-22
Downgrade	SVB Leerink: Outperform → Mkt Perform	May-05-22
Downgrade	Northland Capital: Outperform → Market Perform	May-04-22
Downgrade	Goldman: Neutral → Sell	May-12-21
Resumed	JP Morgan: Neutral	Sep-29-20
Initiated	Piper Sandler: Overweight	Aug-26-20
Initiated	Northland Capital: Outperform	May-05-20
Downgrade	Goldman: Buy → Neutral	Mar-31-20
Downgrade	Jefferies: Buy → Hold	Mar-31-20
Upgrade	Oppenheimer: Underperform → Perform	Mar-31-20
Upgrade	Goldman: Neutral → Buy	Mar-13-20
Initiated	Cowen: Outperform	Mar-02-20
Upgrade	Citigroup: Neutral → Buy	Feb-18-20
Initiated	JP Morgan: Neutral	Jan-06-20
Downgrade	Stifel: Buy → Hold	Dec-16-19
Initiated	Oppenheimer: Underperform	Nov-20-19
Downgrade	Citigroup: Buy → Neutral	Nov-18-19
Reiterated	SVB Leerink: Outperform	Nov-15-19
Initiated	Aegis Capital: Buy	Oct-31-19
Initiated	Goldman: Neutral	Oct-15-19
Initiated	SVB Leerink: Outperform	Aug-14-19
Reiterated	Jefferies: Buy	Jul-09-19
Initiated	ROTH Capital: Buy	Jun-17-19
Initiated	Stifel: Buy	Mar-22-19